UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD.,
Petitioner,

v.

ALEXION PHARMACEUTICALS, INC.
Patent Owner.

Case No. IPR2023-00999
Patent: 9,725,504

DECLARATION OF BERNHARDT L. TROUT, Ph.D.

Mail Stop **PATENT BOARD**
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-145

I, Bernhardt L. Trout, Ph.D., hereby declare and say as follows:

I. INTRODUCTION

1. I am over the age of eighteen (18) and otherwise competent to make this declaration.

2. I have been retained by Alexion Pharmaceuticals, Inc. ("Alexion") as an independent expert consultant in this proceeding brought by Samsung Bioepis Co. Ltd. ("Samsung") before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board ("PTAB"). Although I am being compensated at my normal consulting rate of $1150/hr for the time I spend on this matter, no part of my compensation is dependent on the outcome of this proceeding, and I have no other interest in this proceeding.[1]

3. I was first retained by Alexion in 2019 as an independent expert consultant in proceedings before the PTAB involving three instituted Inter Partes Review ("IPR") trials brought by petitioner Amgen, Inc.: IPR2019-00739 regarding U.S. Pat. No. 9,725,504 (the "'504 patent"); IPR2019-00740 regarding U.S. Pat. No. 9,718,880 (the "'880 patent"); and IPR2019-00741 regarding U.S.

[1] All opinions expressed and implied in this Declaration are solely my own and do not represent or reflect the views of my employer.

Pat. No. 9,732,149 (the "'149 patent") (collectively, "the Amgen IPRs"). I submitted a declaration in the Amgen IPRs instituted against the '504 and '880 patents, which I signed on November 22, 2019 (the "2019 Trout Decl."), and provided testimony via deposition on January 28, 2020. My 2019 Trout Decl. submitted in the Amgen IPRs contains an overview of my experience and qualifications. My place of work has not changed since then, and I continue to work in the same field. A more recent version of my curriculum vitae is attached here as **Appendix A**.

4. I have again been retained by Alexion to act as an independent expert consultant in five IPRs brought by petitioner Samsung: IPR2023-00933 regarding the '149 patent; IPR2023-00998 regarding the '880 patent; IPR2023-00999 regarding the '504 patent; IPR2023-01069 regarding U.S. Pat No. 10,590,189 (the "'189 patent"); and IPR2023-01070 regarding U.S. Pat. No. 10,703,809 (the "'809 patent") (collectively, "the Samsung IPRs"). More specifically, I have been retained by Alexion to again opine on whether, from the perspective of a person of ordinary skill in the art ("POSA") before March 15, 2007, the pharmaceutical compositions recited in claims 1-10 of the '504 patent would have been obvious in view of Bowdish (EX1004), Evans (EX1005), Bell (1007), Tacken (EX1008), Mueller PCT (EX1009), and Wang (EX EX1044).

5. I am also aware that the PTAB has issued Institution Decisions in each of the Samsung IPRs granting Samsung's petitions and instituting trials. I understand that the PTAB's Institution Decisions do "not reflect a final determination on the patentability of the claim." (IPR2023-00999, Paper No. 9 at 66.)

6. I have reviewed and considered Samsung's IPR petition regarding the '504 patent (IPR2023-00999, Paper No. 2), the Ravetch Decl. (*id*. at EX1003) and the Ippoliti Decl. (*id*. at EX1062) regarding the '504 patent, the Institution Decision regarding the '504 patent (*id*. at Paper No. 9), and the other documents cited therein. As already mentioned, it is my opinion that Samsung's "Grounds" in its IPR regarding the '504 patent consist of substantially the same core art and arguments presented in the Amgen IPRs. Accordingly, and as already mentioned, the opinions I provided in the 2019 Trout Decl. are equally applicable to Samsung's IPR regarding the '504 patent. None of the opinions I presented in the 2019 Trout Decl. have changed since its original execution.

7. For these reasons, I expressly adopt and reassert all of my opinions presented in my 2019 Trout Decl. for the purposes of Samsung's IPR against the '504 patent. I understand that my 2019 Trout Decl. from IPR2019-00739 has been submitted to the PTAB as ALXN2024 for use in these proceedings.

8. For the reasons explained in my 2019 Trout Decl. (IPR2023-00999, ALXN2024), it is my opinion that the claims of the ’504 patent are valid over all of the art and arguments presented by Samsung in its IPR regarding the pharmaceutical compositions recited in the claims of the ’504 patent. More specifically, I disagree with Dr. Ravetch’s opinions set forth in the Ravetch Decl. (*id*. at EX1003) and with Dr. Ippoliti’s opinions set forth in the Ippoliti Decl. (*id*. at EX1062) that a POSA would have been motivated to make and use the pharmaceutical compositions claimed in the ’504 patent, or that a POSA would have had a reasonable expectation of success in doing so.

9. I expressly reserve my right to present additional or supplemental opinions as these Samsung IPRs progress.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true. I further declare that I made these statements with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Date: 3/9/24

Bernhardt L. Trout, Ph.D.